Avalo Therapeutics Inc (AVTX)
Avalo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for immune dysregulation in the United States. Its lead program, AVTX-009, is a humanized monoclonal antibody designed to bind interleukin-1ß and is being evaluated in a phase 2 clinical trial for inflammatory diseases. The company was previously known as Cerecor Inc. and adopted its current name in August 2021. Avalo Therapeutics was incorporated in 2011 and is headquartered in Rockville, Maryland. The common stock is listed on the NASDAQ exchange under the ticker AVTX.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AVTX
|
$17.71
|
-2.8% Downside
|
Fair
|
$44.69
|
145.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-11.4x
|
14.2x
|
16,417.9x
|
963.4 M
|
887 M
|
0.0%
|
76.6%
|
9.1
|
—
|
70.4%
|
